Systemic Treatment
Chemotherapy for Cancer
Chemotherapy is systemic cancer treatment that uses drugs to kill rapidly dividing cells. This guide covers drug classes, regimens, side effects, costs and what to ask your oncology team.
What is Chemotherapy?
Systemic treatment using cytotoxic drugs that kill rapidly dividing cells. Circulates throughout bloodstream reaching cancer anywhere in body. Given alone or combined with surgery, radiation, immunotherapy.
Treatment Schedule
Cycles of treatment followed by rest (2-4 weeks typically). IV infusion (30 minutes - 6 hours), oral pills daily, or injections. Duration: 3-6 months curative intent, ongoing for palliative/maintenance.
Highly Curable Cancers
Testicular (95% cure with chemo), Hodgkin lymphoma (90%), gestational trophoblastic (95%), childhood leukemia (90%), many lymphomas. Chemotherapy cornerstone of cure in these diseases.
Side Effects
Nausea/vomiting (controlled with antiemetics), hair loss (temporary), fatigue, bone marrow suppression (infection/bleeding risk), peripheral neuropathy. Vary by regimen. Most resolve after completing treatment.
What is Chemotherapy?
Chemotherapy is systemic cancer treatment using cytotoxic (cell-killing) drugs that target rapidly dividing cells. Unlike surgery (removes localized tumor) or radiation (treats specific area), chemotherapy circulates throughout bloodstream, reaching cancer cells anywhere in the body—making it essential for treating metastatic disease, microscopic spread, and systemic cancers like leukemia/lymphoma.
The term "chemotherapy" technically encompasses all drug therapy, but colloquially refers to traditional cytotoxic agents (distinct from newer targeted therapies like tyrosine kinase inhibitors or immunotherapy). These drugs don't distinguish cancer from normal rapidly dividing cells (hair follicles, GI lining, bone marrow)—explaining characteristic side effects like hair loss, nausea, immunosuppression.
Treatment Intent Categories
1. Neoadjuvant Chemotherapy (Before Surgery):
Goal: Shrink tumor facilitating surgery, test tumor's chemosensitivity in vivo, treat micrometastases early. Breast cancer: 2-6 cycles before mastectomy/lumpectomy. Rectal cancer: chemoradiation before resection. Esophageal cancer: perioperative chemotherapy improves outcomes. Pathologic complete response (pCR—no viable tumor at surgery) strong prognostic indicator—signals chemosensitive cancer, excellent prognosis.
2. Adjuvant Chemotherapy (After Surgery):
Goal: Eliminate microscopic residual disease, prevent recurrence. Surgery removes macroscopic tumor; adjuvant chemo addresses undetectable micrometastases. Breast cancer: 4-8 cycles post-surgery reduces recurrence 30-50% depending on subtype. Colon cancer stage III: 6 months FOLFOX (5-FU, oxaliplatin) reduces recurrence 30%, improves survival 10-15%. Duration typically 3-6 months—longer doesn't improve outcomes, increases toxicity.
3. Definitive/Primary Chemotherapy:
Cancers highly chemosensitive—chemotherapy alone curative without surgery/radiation. Testicular cancer, Hodgkin lymphoma, many non-Hodgkin lymphomas, gestational trophoblastic disease, childhood leukemia. Also advanced metastatic solid tumors where surgery/radiation not curative—chemotherapy palliation/life-extension.
4. Palliative Chemotherapy:
Goal: Control symptoms, improve quality of life, extend survival in incurable metastatic cancer. Not curative intent but meaningful benefits: pain reduction, shrinking obstructive tumors, slowing progression. Balance benefit vs toxicity—quality of life paramount. Some patients choose palliative chemo (months life extension); others decline (minimize toxicity, focus on comfort).
5. Maintenance Chemotherapy:
Continuing single-agent chemotherapy after initial treatment response. Ovarian cancer: bevacizumab or PARP inhibitor maintenance prolongs progression-free survival. Lung cancer: pemetrexed maintenance post-induction. Ongoing low-dose treatment preventing/delaying progression.
How Chemotherapy Works
Mechanisms of Action (Drug Classes)
Alkylating Agents (Cyclophosphamide, Cisplatin, Carboplatin)
Mechanism: Directly bind and crosslink DNA strands, preventing separation during replication. Cell dies attempting division. Cell-cycle nonspecific (works any phase).
Common regimens: Cisplatin backbone for lung, ovarian, bladder, head/neck cancers. Cyclophosphamide in lymphomas (CHOP regimen). Carboplatin in ovarian (carboplatin/paclitaxel standard).
Side effects: Nausea/vomiting (severe with cisplatin—pre-medications essential), kidney toxicity (cisplatin—requires IV hydration), hearing loss (cisplatin), peripheral neuropathy (platinum agents).
Antimetabolites (5-FU, Gemcitabine, Methotrexate, Pemetrexed)
Mechanism: Mimic building blocks of DNA/RNA, incorporating into replication process, creating non-functional molecules. Cells die from faulty DNA/RNA. Cell-cycle specific (S-phase—DNA synthesis).
Usage: 5-FU backbone colorectal cancer (FOLFOX: 5-FU + oxaliplatin + leucovorin). Gemcitabine pancreatic, bladder, lung cancers. Pemetrexed lung cancer maintenance. Methotrexate lymphomas, breast.
Side effects: GI toxicity (diarrhea, mucositis), hand-foot syndrome (5-FU), bone marrow suppression. Generally better tolerated than alkylating agents.
Anthracyclines (Doxorubicin/Adriamycin, Epirubicin)
Mechanism: Intercalate DNA (insert between base pairs), inhibit topoisomerase II (enzyme managing DNA tangles), generate free radicals. Triple mechanism—highly effective but toxic.
Usage: Lymphomas (CHOP, ABVD), breast cancer (AC, FEC regimens), sarcomas. Among most effective chemo drugs but limited by cardiotoxicity.
Cardiotoxicity: Cumulative lifetime dose limits (doxorubicin ≤450-550 mg/m²). Heart failure risk 5-10% at max doses. MUGA/echo monitoring cardiac function during treatment. Liposomal formulations (Doxil) reduce cardiotoxicity, enable higher cumulative doses.
Taxanes (Paclitaxel, Docetaxel)
Mechanism: Stabilize microtubules (normally dynamic structures cells use for division), preventing mitotic spindle function. Cells arrested in M-phase, undergo apoptosis.
Usage: Breast cancer (standard adjuvant, metastatic), ovarian (carboplatin/paclitaxel), lung, head/neck. Weekly low-dose or every-3-week high-dose schedules.
Side effects: Peripheral neuropathy (dose-limiting—fingers/toes numbness, tingling, pain; 20-40% severe cases), hair loss, bone marrow suppression, hypersensitivity reactions (pre-medications required).
Vinca Alkaloids (Vincristine, Vinblastine)
Microtubule inhibitors (opposite taxanes—prevent assembly). Lymphoma regimens (CHOP, ABVD), childhood leukemia. Neuropathy dose-limiting (vincristine). Constipation characteristic (autonomic neuropathy affecting bowel).
Why Combination Chemotherapy?
Synergy: Different mechanisms attack cancer multiple pathways. Cell resistant to one drug killed by another. FOLFOX (colon): 5-FU (antimetabolite) + oxaliplatin (alkylator)—response 50% vs 20-30% single-agent.
Preventing resistance: Cancer cells mutate rapidly. Single-agent therapy: resistant clones emerge. Combination therapy: simultaneously resistant to 3-4 drugs exponentially less likely.
Non-overlapping toxicities: Combining drugs with different toxicity profiles allows each at full/near-full dose. Example: Cisplatin (kidney-toxic) + paclitaxel (nerve-toxic) tolerated together; both cisplatin + carboplatin (both kidney-toxic) can't combine at full doses.
Common Chemotherapy Regimens by Cancer Type
Breast Cancer
AC-T (Doxorubicin/Cyclophosphamide followed by Paclitaxel): Standard adjuvant. 4 cycles AC every 2-3 weeks, then 4 cycles weekly paclitaxel. Total: 16-20 weeks. Cure contribution: 25-35% reduction recurrence risk.
TCH (Docetaxel, Carboplatin, Herceptin): HER2-positive cancers. Chemo + targeted therapy (trastuzumab). Avoids anthracycline cardiotoxicity while maintaining efficacy.
Colorectal Cancer
FOLFOX (5-FU, Leucovorin, Oxaliplatin): Adjuvant stage III colon, first-line metastatic. Every 2 weeks x 12 cycles (6 months). Response rate 50-60% metastatic disease.
FOLFIRI (5-FU, Leucovorin, Irinotecan): Alternative to FOLFOX or second-line. Different toxicity (diarrhea vs neuropathy). Sequential FOLFOX→FOLFIRI exposes to both drugs over disease course.
Lung Cancer (NSCLC)
Platinum doublets: Cisplatin or carboplatin + paclitaxel/pemetrexed/gemcitabine. 4 cycles standard. Response 25-35%. Now often combined with pembrolizumab immunotherapy (improved outcomes).
Maintenance: Pemetrexed continuation after induction for non-squamous NSCLC. Prolongs progression-free survival 3-4 months.
Ovarian Cancer
Carboplatin/Paclitaxel: Gold standard. 6 cycles every 3 weeks. Response 70-80%. Maintenance options: bevacizumab (anti-VEGF), PARP inhibitors (BRCA-mutated).
Lymphomas
CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): Aggressive non-Hodgkin lymphomas. Every 3 weeks x 6 cycles. Cure 50-60% when combined with rituximab (R-CHOP).
ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine): Hodgkin lymphoma. 6-8 cycles. Cure 80-90% early-stage (with radiation), 60-70% advanced-stage.
Testicular Cancer
BEP (Bleomycin, Etoposide, Cisplatin): 3-4 cycles. Cures 95%+ even metastatic disease. One of medicine's great success stories—universally fatal pre-chemotherapy era; now highly curable.
Chemotherapy Delivery & Treatment Day Experience
Delivery Routes
Intravenous (IV) - Most Common:
Peripheral IV (small hand/arm veins): OK for short infusions, non-vesicant drugs. Uncomfortable after multiple treatments—vein damage, difficulty accessing. Port (mediport, port-a-cath): Surgically implanted device under skin (chest) with catheter into large central vein. Accessed with special needle. Removes easily when completing treatment. Indicated for vesicant drugs (doxorubicin—causes tissue necrosis if extravasates), long infusions, frequent treatments, poor peripheral access. Minor infection risk (<1 per 1000 catheter-days), thrombosis rare. Most patients prefer port—convenience outweighs minor surgery.
Oral Chemotherapy: Capecitabine (5-FU prodrug), temozolomide (glioblastoma), cyclophosphamide (low-dose chronic). Convenience of at-home treatment. Requires excellent compliance—missing doses reduces efficacy. Insurance sometimes covers IV better than oral (illogical but reality). Toxicity monitoring still needed—blood work, clinic visits.
Intrathecal: Direct injection into cerebrospinal fluid (spinal tap or Ommaya reservoir). CNS prophylaxis for leukemia, lymphoma (prevent brain/spine involvement). Methotrexate, cytarabine. Systemic chemo doesn't penetrate blood-brain barrier well—intrathecal delivery needed.
Intraperitoneal: Direct delivery into abdominal cavity. Ovarian cancer (HIPEC—hyperthermic intraperitoneal chemotherapy during surgery). High local concentrations, lower systemic toxicity. Technically demanding, not widely available.
What Infusion Day is Like
- Step 1Blood Work & Assessment
CBC (complete blood count) checks white cells, platelets, hemoglobin before each cycle. Minimum thresholds required (ANC ≥1,500, platelets ≥100,000) confirming bone marrow recovered. Metabolic panel checks kidney/liver function. Vitals, weight, toxicity assessment by nurse. If counts inadequate: delay treatment 1 week (allows recovery), dose-reduce (if multiple delays), or add growth factors (GCSF injections stimulating WBC production).
- Step 2Pre-Medications
Anti-nausea (ondansetron, dexamethasone, aprepitant) 30-60 minutes before chemotherapy. Highly emetogenic regimens (cisplatin, doxorubicin): triple-drug antiemetic prophylaxis. Pre-medications prevent/minimize nausea—most patients tolerate well with modern antiemetics (contrast to past when nausea debilitating).
Hypersensitivity prophylaxis: Antihistamine, corticosteroid before paclitaxel/docetaxel (prevent allergic reactions).
- Step 3Chemotherapy Infusion
IV bag or pump infusion. Duration varies: cisplatin (1-2 hours), carboplatin (30 min), paclitaxel (3 hours), 5-FU (continuous 46-hour infusion via portable pump). Reclining chairs, private/semi-private bays. Can read, work on laptop, sleep, eat/drink. Nurse checks frequently. Total time in infusion center: 2-8 hours depending on regimen.
- Step 4Post-Infusion & Recovery
Disconnect IV, flush port, go home. Post-infusion nausea peaks 24-72 hours (delayed nausea)—take-home antiemetics prescribed. Fatigue worsens days 2-7 post-chemo. Blood counts nadir (lowest point) days 7-14—infection risk highest then. Recover week 3-4, ready for next cycle.
Chemotherapy Side Effects & Management
Common Side Effects (Prevalence & Management)
Nausea & Vomiting (40-70%)
Acute: 0-24 hours post-chemo. Prevented with pre-medications (5-HT3 antagonists, NK1 antagonists, dexamethasone). Delayed: 24-120 hours post. Requires take-home antiemetics. Anticipatory: Conditioned response before treatment (triggered by smells, sights associated with chemo). Behavioral therapy, lorazepam help.
Breakthrough: If nausea occurs despite prophylaxis, add rescue medications (metoclopramide, prochlorperazine, olanzapine). Modern antiemetics control nausea 80-90% patients. Severe nausea now uncommon with proper management.
Hair Loss - Alopecia (60-100% with anthracyclines/taxanes)
Starts 2-3 weeks after first dose. Complete scalp hair loss by 4-6 weeks. Body hair thins. Emotionally distressing (visible cancer sign). Temporary: Regrows 1-3 months after completing chemotherapy. New growth often different texture (curly if was straight), sometimes different color. Eventually returns to baseline.
Prevention: Scalp cooling (cold caps) reduces hair loss 50-80% by vasoconstricting scalp during infusion (less drug delivered to follicles). Time-consuming (before/during/after infusion), uncomfortable (headache from cold), expensive ($1,500-$3,000 course), not always covered. Many patients choose acceptance + wigs/scarves.
Bone Marrow Suppression (80-100%)
Neutropenia (low white blood cells): Infection risk. Nadir day 7-14. Fever (≥100.4°F) during neutropenia = oncologic emergency—ER, blood cultures, broad-spectrum IV antibiotics (Gram-negative coverage). Febrile neutropenia (FN) carries 5-10% mortality if untreated.
GCSF (Neupogen, Neulasta): Growth factor injections stimulating WBC production. Reduces FN risk 50%. Indications: FN previous cycle, high-risk regimens (dose-dense AC), age >65. Self-administered day after chemo or long-acting pegfilgrastim single injection. Bone pain common side effect (marrow expansion).
Thrombocytopenia (low platelets): Bleeding risk. Transfuse if <10,000 (spontaneous bleeding risk) or <50,000 with bleeding/pre-procedure. Delay chemo until >100,000.
Anemia: Fatigue, dyspnea. Transfuse if symptomatic + Hgb <7-8. Erythropoietin (EPO) stimulates RBC but thrombosis risk—limited use.
Peripheral Neuropathy (30-60% platinum/taxanes)
Cumulative dose-dependent. Numbness, tingling ("glove-stocking" distribution—fingers/toes first), neuropathic pain, loss of fine motor skills (buttoning, writing). Mild: annoying. Severe: functional impairment, falls, permanent disability.
Management: Dose reduction or discontinuation if severe (prevents progression—existing neuropathy may improve but often persists). Duloxetine (SNRI) modest benefit. Gabapentin, pregabalin for neuropathic pain. Prevention: none proven (calcium/magnesium infusions, glutathione unproven). Neuropathy major quality-of-life issue—dose-limiting for many.
Other Significant Toxicities
- Mucositis (mouth sores): 5-FU, methotrexate. Painful ulcers, difficulty eating. Cryotherapy (ice chips during infusion) reduces oral 5-FU mucositis. Magic mouthwash (lidocaine + antacid), pain control. Resolves 1-2 weeks.
- Diarrhea: 5-FU, irinotecan. Loperamide first-line. Severe (>6 stools/day): hospitalization, IV fluids. Irinotecan: early diarrhea (cholinergic—during infusion, treated with atropine), late diarrhea (days 5-10, treat with loperamide).
- Hand-foot syndrome: Capecitabine, continuous-infusion 5-FU. Painful palmar-plantar erythema, peeling, blistering. Vitamin B6 (pyridoxine) helps. Dose reduction if severe.
- "Chemo brain" (cognitive dysfunction): Subtle memory, concentration, multitasking deficits during/after chemotherapy. 20-30% report. Mechanisms unclear (direct neurotoxicity, inflammation, hormonal changes). Improves 6-12 months post-treatment but some persistent deficits. Frustrating—often dismissed but real quality-of-life impact.
Curative Chemotherapy: Success Stories
Despite toxicity, chemotherapy cures many cancers that were uniformly fatal in pre-chemotherapy era. Testicular cancer, Hodgkin lymphoma, childhood leukemia transformed from death sentences to >90% cure rates. For many cancers, chemotherapy is essential component of multidisciplinary cure.
Highly Chemocurable Cancers
Testicular Cancer (95-98% Cure Rate)
Even metastatic disease curable with BEP chemotherapy. 3 cycles good-risk, 4 cycles intermediate/poor-risk. Side effects significant (nausea, hearing loss, neuropathy, bleomycin lung toxicity) but worthwhile given cure rates. Post-chemo surgery (retroperitoneal lymph node dissection) for residual masses. Long-term survivorship excellent—most young men return completely normal lives.
Hodgkin Lymphoma (85-95% Cure Rate)
ABVD standard. Early-stage (I-II): 2-4 cycles + involved-site radiation—cure >90%. Advanced-stage (III-IV): 6 cycles—cure 70-80%. Relapsed disease: salvage chemo + autologous stem cell transplant rescues additional 40-50%. Cure rates continue improving with escalation/de-escalation strategies, PET-adapted therapy.
Childhood Acute Lymphoblastic Leukemia (ALL)
90% cure rate with multi-agent chemotherapy (vincristine, daunorubicin, asparaginase, corticosteroids, methotrexate, 6-MP). Treatment 2-3 years. Intensity/toxicity high but justified by cure rates. CNS prophylaxis (intrathecal methotrexate) prevents brain relapse. Triumph of pediatric oncology—was universally fatal; now most children cured.
Gestational Trophoblastic Neoplasia
Rare placental tumors. Single-agent methotrexate cures 90% low-risk. High-risk: EMA-CO regimen cures 90-95%. Preserves fertility—women have healthy pregnancies post-treatment. Monitor hCG (tumor marker) until undetectable.
Adjuvant Chemotherapy Contribution to Cure
Breast cancer: Adjuvant chemotherapy reduces recurrence risk 25-35%, mortality 15-25% (varies by subtype). Triple-negative: chemotherapy only systemic option (no hormonal/HER2 therapy)—essential.
Colon cancer stage III: 6 months FOLFOX improves 5-year survival from 65% (surgery alone) to 75-80% (surgery + chemo).
Ovarian cancer: Debulking surgery + carboplatin/paclitaxel improves 5-year survival from 20% (surgery alone) to 40-50%.
Palliative Chemotherapy
For metastatic solid tumors (colon, lung, breast, pancreas stage IV), chemotherapy rarely curative but provides meaningful benefits: symptom relief, slows progression, extends survival months to years. Whether benefit justifies toxicity depends on regimen, cancer type, performance status, patient values.
Survival Benefits (Median Survival Extension)
- Metastatic colorectal: Best supportive care (no chemo) 6 months. Sequential FOLFOX, FOLFIRI, targeted agents (bevacizumab, cetuximab): 24-30 months. 2-year survival improvement.
- Metastatic pancreatic: No chemo 3-4 months. FOLFIRINOX (intensive): 11 months. Gemcitabine/nab-paclitaxel: 8 months. Benefit modest but meaningful (4-8 months extension, symptom control).
- Metastatic lung (NSCLC): No chemo 4-5 months. Platinum doublet: 8-10 months. Addition of immunotherapy: 15-20 months (if PD-L1 high). Dramatic improvement with immunotherapy era.
- Metastatic breast (HER2-negative): Varies by hormone receptor status, prior treatments. Sequential single agents (anthracycline, taxane, capecitabine, eribulin): median OS 2-3 years from metastasis. Some live 5-10+ years with ongoing treatments.
Quality vs Quantity of Life
Palliative chemotherapy trade-off: months survival extension vs toxicity burden. Intensive regimens (FOLFIRINOX—pancreatic cancer): 4-month survival gain but severe toxicity 50% patients. Gentler regimens (gemcitabine): 1-month gain, tolerable. Patient choice: some prioritize survival extension accepting toxicity; others prioritize quality accepting shorter duration. Honest discussion of benefits/toxicity essential.
When to Stop Palliative Chemotherapy
ASCO guidelines: Discontinue if performance status declined (ECOG 3-4—bedridden >50% day), no symptom benefit, progressive disease despite 2-3 regimens. Transition to hospice/palliative care focusing on comfort. Chemotherapy near end-of-life reduces quality of life without meaningful survival benefit.
Chemotherapy Costs
Cost Variability
Chemotherapy costs vary enormously: generic drugs (5-FU, cyclophosphamide) cheap ($100-500/cycle); newer agents (carboplatin/paclitaxel) moderate ($2,000-5,000/cycle); targeted therapies (bevacizumab, trastuzumab) expensive ($5,000-15,000/cycle). Full treatment course: $10,000-$200,000 depending on regimen.
Example: Colon Cancer Adjuvant FOLFOX (6 months/12 cycles)
United States
$60,000 - $100,000Includes drugs, infusion center fees, physician visits, labs, port placement, complications management. Insurance-covered (after deductible/copay). Out-of-pocket: $3,000-$15,000 depending on plan.
Turkey
$12,000 - $20,000Complete treatment package. Internationally accredited oncology centers. Original drugs (not counterfeit). English-speaking oncologists. 70-80% savings vs USA.
India
$8,000 - $15,000Budget-friendly option. Generic drugs widely available. Quality varies—choose internationally accredited centers. Significant savings, longer travel required.
Mexico
$15,000 - $25,000Proximity to USA. Some insurance cross-coverage. Modern facilities (border cities, Mexico City). Easier logistics for US patients than Asia/Europe.
Financial Assistance
- Manufacturer copay cards: Reduce out-of-pocket for insured patients (Roche, Amgen, BMS programs).
- Patient assistance programs: Free medication for uninsured/underinsured meeting income criteria.
- Nonprofit organizations: Cancer Care, Leukemia & Lymphoma Society, Patient Advocate Foundation provide financial grants.
- Hospital financial counselors: Navigate assistance programs, payment plans, charity care.
- Clinical trials: Investigational drug provided free (trial sponsor pays). Standard-of-care drugs in trial sometimes covered by insurance, sometimes by sponsor.
Frequently Asked Questions
Can I work during chemotherapy?
Answer: Many patients work full/part-time during treatment. Depends on regimen intensity, job physical demands, fatigue level. Desk jobs often feasible. Heavy labor challenging. Some employers accommodate modified schedules, work-from-home. Disability leave option if cannot work. Discuss with oncologist, employer HR/disability office.
Will I definitely lose my hair?
Answer: Not all chemo causes hair loss. Anthracyclines, taxanes: nearly 100%. Platinum agents (cisplatin, carboplatin): thinning but not complete loss usually. 5-FU, capecitabine: minimal hair loss. Targeted therapies (not traditional chemo): usually no hair loss. Your oncologist can specify based on your regimen.
Should I eat special diet during chemo?
Answer: No specific "cancer diet" proven beneficial. Maintain good nutrition—adequate protein, calories. Avoid: raw/undercooked foods (infection risk during neutropenia), excessive supplements (antioxidants may interfere with chemo/radiation). Ginger for nausea. Small frequent meals vs large meals. Dietitian consultation helpful—especially if weight loss, mucositis affecting intake.
Can I drink alcohol during chemotherapy?
Answer: Moderate alcohol generally OK (1 drink occasionally) unless liver dysfunction or interacting medications. Excessive alcohol worsens nausea, liver toxicity, neuropathy. Avoid during nadir (days 7-14—immune system lowest). Ask oncologist about specific regimen—some drugs (methotrexate) alcohol absolutely contraindicated.
How do you know if chemotherapy is working?
Answer: Imaging (CT, PET) every 2-3 cycles assesses response. Complete response (CR): All visible cancer disappeared. Partial response (PR): ≥30% tumor shrinkage. Stable disease (SD): Not growing/shrinking. Progressive disease (PD): ≥20% growth or new lesions. CR/PR: continue same regimen. SD: sometimes continue if symptoms improved. PD: switch regimen or discontinue.
Tumor markers (CEA colon, CA-125 ovarian, PSA prostate) trend correlates with response but imaging definitive.
What happens if chemotherapy stops working?
Answer: Switch to different regimen (second-line, third-line chemotherapy). Each subsequent line: lower response rates, shorter duration of benefit. Eventually: chemotherapy exhausted, cancer resistant. Options: clinical trial (new agents, combinations), immunotherapy if not tried, palliative/hospice care. Median lines of therapy metastatic disease: 2-4 before transitioning to comfort care.
Can chemotherapy cause other cancers?
Answer: Rare but yes. Alkylating agents, anthracyclines, etoposide associated with therapy-related myelodysplastic syndrome (t-MDS) or acute myeloid leukemia (t-AML) years later. Risk <1% most regimens, higher (2-5%) with intensive treatments (transplant conditioning). Latency 5-10 years. Risk-benefit strongly favors treatment—curing/controlling current cancer outweighs small future cancer risk.
Can I have children after chemotherapy?
Answer: Depends on drugs, doses, age. Women: Alkylating agents (cyclophosphamide) most gonadotoxic. Age >35 higher infertility risk (lower ovarian reserve). Fertility preservation: egg/embryo freezing before starting chemo. Post-chemo: fertility may recover (especially younger women) or permanent ovarian failure. Men: Sperm banking before chemo standard. Many regimens cause azoospermia (no sperm)—sometimes recovers 1-3 years post, sometimes permanent. Discuss fertility preservation with oncologist before starting treatment.